Mercury Pharmaceuticals

We are de-risking biomedical innovations, while turning biomedical knowledge into social and economic value.

Stay Informed!

Ageing slows brain protein clearance and shifts synaptic waste to microglia

22

Jan 2026

Ageing slows brain protein clearance and shifts synaptic waste to microglia

Ageing slows neuronal protein degradation in mice, leading to widespread accumulation and aggregation of long-lived proteins, particularly at synapses. As neuronal clearance declines, microglia selectively accumulate synaptic proteins, suggesting a compensatory but potentially strained proteostasis pathway in the ageing brain.

Nearly half of adults now live with heart disease as obesity and diabetes surge

22

Jan 2026

Nearly half of adults now live with heart disease as obesity and diabetes surge

The 2026 American Heart Association Heart Disease and Stroke Statistics report shows that nearly half of adults are living with cardiovascular disease, with cardiometabolic risk factors projected to rise substantially by 2050. Despite progress in smoking reduction and cholesterol control, worsening obesity, diabetes, hypertension, sleep health, and persistent inequities threaten future cardiovascular health.

Cancer vaccines enter a new era of personalized immunotherapy

22

Jan 2026

Cancer vaccines enter a new era of personalized immunotherapy

A new comprehensive review from researchers at the Icahn School of Medicine at Mount Sinai details how decades of cancer vaccine research are converging into a new era of more precise, personalized, and effective immunotherapies, particularly when combined with other cancer treatments.

MERCURY trials

Clinical trials are very important as it allow us to evaluate the effectiveness of new drugs, new devices, preventative strategies or treatment strategies. It also enables us to discover better ways for patients' care.
- Learn more

Cancer

Our mission remains constant as we endeavor to deliver novel medicines to patients with cancer, treating solid tumors with high unmet medical needs in well-defined patient populations that are currently not well supported.
- Learn more

Neuroscience

Whether you're looking to manufacture toxicology batches or cGMP material for clinical trials, we can help you expedite molecules to clinic with full transparency.
- Learn more

Mercury Pharmaceuticals

Why Us?

Strong experience in academic research and technology transfer makes us understand your goals and motivations as a technology originator.
Our experience in drug development from discovery to clinical and commercial stages makes us an insider player within the biopharmaceutical industry.
Smart approach to project management that helps speed up development stages and decision making.
Availability of own investment up to 2m€ per project allows us to reach the next value milestone.